Drug Profile
Delafloxacin - Melinta Therapeutics
Alternative Names: ABT-492; Baxdela; Quofenix; RX-3341; RX-3341-83; WQ-3034Latest Information Update: 05 Nov 2018
Price :
$50
*
At a glance
- Originator Wakunaga Pharmaceutical
- Developer Abbott Laboratories; Eurofarma; Melinta Therapeutics; Menarini
- Class Antibacterials; Azetidines; Fluoroquinolones; Pyridines; Small molecules
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Skin and soft tissue infections
- Phase III Community-acquired pneumonia
- Phase I Urinary tract infections
- Discontinued Acute exacerbations of chronic bronchitis; Anthrax; Gonorrhoea; Intra-abdominal infections
Most Recent Events
- 29 Oct 2018 Melinta Therapeutics announced intention to submit supplemental NDA to USFDA for community-acquired bacterial pneumonia in the first half of 2019
- 29 Oct 2018 Efficacy and adverse events data from a phase III trial in Community-acquired bacterial pneumonia released by Melinta Therapeutics
- 07 Aug 2018 Melinta Therapeutics completes the phase III DEFINE-CABP trial in Community-acquired pneumonia in Ukraine, Spain, Slovenia, Serbia, Russia, Romania, Poland, Latvia, Hungary, Germany, Georgia, Bulgaria, USA (IV) (NCT02679573)